<DOC>
	<DOCNO>NCT02979613</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy , safety , tolerability switch tenofovir alafenamide ( TAF ) versus continue tenofovir disoproxil fumarate ( TDF ) virologically suppress adult chronic hepatitis B virus ( HBV ) infection .</brief_summary>
	<brief_title>Efficacy Safety Switching From TDF TAF Adults With Chronic Hepatitis B Who Are Virologically Suppressed</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Key Must ability understand sign write informed consent form ; consent must obtain prior initiation study procedure Adult male nonpregnant , nonlactating female Documented evidence chronic HBV infection previously Maintained TDF 300 mg QD least 48 week , monotherapy chronic hepatitis B least 24 week viral suppression ( HBV DNA &lt; LLOQ ) minimum 12 week prior screen Adequate renal function Normal ECG Key Pregnant woman woman breastfeed Males female reproductive potential unwilling use `` effective '' , protocolspecified method ( ) contraception study . Coinfection hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) , HIV Evidence hepatocellular carcinoma Current evidence , recent ( ≤ 5 year ) history clinical hepatic decompensation Abnormal hematological biochemical parameter , include : Platelets ≤ 50,000/mm^3 Aspartate aminotransferase ( AST ) ALT &gt; 5 × upper limit normal range ( ULN ) Albumin &lt; 3.0 mg/ dL International normalize ratio ( INR ) &gt; 1.5 × ULN ( unless stable anticoagulant regimen ) Total bilirubin &gt; 2.5 × ULN Received solid organ bone marrow transplant Malignancy within 5 year prior screen , exception specific cancer cure surgical resection ( eg , basal cell skin cancer ) . Individuals evaluation possible malignancy eligible . Currently receive therapy immunomodulators ( eg , corticosteroid ) , nephrotoxic agent , agent capable modify renal excretion Individuals receive ongoing therapy drug use tenofovir alafenamide tenofovir disoproxil fumarate individual know hypersensitivity study drug , metabolite , formulation excipients Current alcohol substance abuse judge investigator potentially interfere compliance Any clinical condition prior therapy , opinion investigator , would make individual unsuitable study unable comply dose requirement . Use investigational agent within 3 month screen , unless allow sponsor Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>